产品说明书

Pirarubicin

Print
Chemical Structure| 72496-41-4 同义名 : THP;NSC-333054
CAS号 : 72496-41-4
货号 : A154529
分子式 : C32H37NO12
纯度 : 98%+
分子量 : 627.64
MDL号 : MFCD00869742
存储条件：

粉末 Keep in dark place,Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 9 mg/mL(14.34 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • Topo II
描述 Pirarubicin is a cell cycle nonspecific anthracycline anticancer drug[3]. It interacts with topoisomerase II to inhibit DNA replication. Pirarubicin inhibits the growth of human HeLa and C33A cervical, as well as T-24 bladder cancer cells (IC50s = 29, 52, and 36 ng/ml, respectively)[4]. It inhibits the growth of human Huh7 and MHCC97H liver cancer cells (IC50s = 0.159 and 0.374 μM, respectively)[5]. Pirarubicin also inhibits the growth of M5076 mouse ovarian cancer cells in vitro (IC50 = 0.366 μM) and in vivo in a mouse allograft model when administered at a dose of 2 mg/kg for four days[6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03277716 Hepatocellular Carcinoma Non-r... 展开 >>esectable Transarterial Chemoembolization Microwave Ablation 收起 << Not Applicable Recruiting December 30, 2021 China, Beijing ... 展开 >> Cancer Institute &Hospital, Chinese Academy of Medical Sciences Not yet recruiting Beijing, Beijing, China, 100021 Contact: Xiao Li, M.D          China, Fujian The First Affiliated Hospital of Fujian Medical University Recruiting Fuzhou, Fujian, China, 350005 Contact: Zhenyu Lin, M.D.          The tumor hospital of Fujian Province Not yet recruiting Fuzhou, Fujian, China, 350014 Contact: Hailan Lin, M.D          China, Guangdong the First Affiliated Hospital of SunYat-senUniversity Not yet recruiting Guangzhou, Guangdong, China, 510080 Contact: Jiaping Li, M.D          Shenzhen People's Hospital Recruiting Shenzhen, Guangdong, China, 518020 Contact: Yanfang Zhang, M.D.          Peking University Hospital of Shenzhen Recruiting Shenzhen, Guangdong, China, 518036 Contact: Junhui Chen, M.D.          China, Shandong The Second Affiliated Hospital of Shandong University Recruiting Jinan, Shandong, China, 250000 Contact: Yuliang Li, M.D          Shandong Province Hospital Recruiting Jinan, Shandong, China, 250014 Contact: Xin Ye, M.D          the Affiliated Hospital of Medical College Qingdao University Recruiting Qingdao, Shandong, China, 26555 Contact: Zixiang Li, M.D          China, Zhejiang The First Affiliated Hospital of Zhejiang University Not yet recruiting Hangzhou, Zhejiang, China, 310003 Contact: Junhui Sun, M.D. 收起 <<
NCT00131053 Lymphoblastic Leukemia, Acute Phase 2 Unknown September 2011 Japan ... 展开 >> Department of Hematology, Nagoya University Graduate School of Medicine Recruiting Nagoya, Japan, 466-8550 Contact: Fumihiko Hayakawa, MD       bun-hy@med.nagoya-u.ac.jp    Principal Investigator: Fumihiko Hayakawa, MD 收起 <<
NCT02760953 Urinary Bladder Neoplasms Not Applicable Not yet recruiting December 31, 2018 -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.59mL

0.32mL

0.16mL

7.97mL

1.59mL

0.80mL

15.93mL

3.19mL

1.59mL
参考文献

[1]Liu SY, Song SX, et al. Molecular mechanism of cell apoptosis by paclitaxel and pirarubicin in a human osteosarcoma cell line. Chemotherapy. 2010;56(2):101-7.

[2]Sugiyama T, Sadzuka Y, et al. Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin. Jpn J Cancer Res. 1999 Jul;90(7):775-80.

[3] Huang H, Chen T, Zhou Y, et al. RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma. Int J Med Sci. 2018;15(14):1648-1657.

[4]Tsuchiya KS, Ishii T, Ikeno S, et al. Inhibition of anchorage-independent growth of tumor cells by IT-62-B, a new anthracycline. J Antibiot (Tokyo). 1997;50(10):853-859.

[5]Huang H, Chen T, Zhou Y, Geng L, Shen T, Zhou L, Zheng S. RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma. Int J Med Sci. 2018 Nov 5;15(14):1648-1657.

[6]Sugiyama T, Sadzuka Y, Nagasawa K, Ohnishi N, Yokoyama T, Sonobe T. Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin. Jpn J Cancer Res. 1999;90(7):775-780.